Recent Updates
Recently added Catalysts
JAZZ Positive Sentiment Score: 70/100

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan...

Key Takeaway: Jazz Pharmaceuticals has announced that it will webcast its corporate presentation at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. CEO Bruce Cozadd will present an overview of the company along with a business and financial update. The presentation will be accessible through the Investors section of Jazz Pharmaceuticals' website. A replay will also be available for 30 days after the conference, enhancing investor access to the information shared.

Market Sentiment Analysis

POSITIVE FACTORS

  • Jazz Pharmaceuticals is providing an overview and financial update, indicating transparency.
  • The company is focused on innovating life-changing medicines for serious diseases.
  • Webcast accessibility allows broader investor engagement.

Full Press Release Details

DUBLIN , Dec. 20, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that the Company will webcast its corporate presentation at the 42 nd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 8, 2024 , at 2:15 p.m. PST / 10:15 p.m. GMT .
A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations . A replay of the webcast will be available on the website for 30 days following the conference.
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.
Investors: Andrea N. Flynn , Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland , +353 1 634 3211 U.S., +1 650 496 2717
Media: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc [email protected] Ireland , +353 1 637 2141 U.S., +1 215 867 4948
SOURCE Jazz Pharmaceuticals plc

21 %

Frequently Asked Questions

When is Jazz Pharmaceuticals' presentation at the J.P. Morgan Conference?

The presentation is on January 8, 2024, at 2:15 p.m. PST.

Where can I watch the Jazz Pharmaceuticals webcast?

The webcast can be accessed via the Investors section of their website.

How long will the webcast replay be available?

The replay will be available for 30 days after the conference.

What areas does Jazz Pharmaceuticals focus on?

Jazz specializes in neuroscience and oncology, developing innovative medicines.

Where is Jazz Pharmaceuticals headquartered?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Last updated: Dec 20, 2023